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ABSTRACT
Background: A low-calorie diet (LCD) reduces fat mass excess,
improves insulin sensitivity, and alters adipose tissue (AT) gene
expression, yet the relation with clinical outcomes remains unclear.
Objective: We evaluated AT transcriptome alterations during an
LCD and the association with weight and glycemic outcomes both
at LCD termination and 6 mo after the LCD.
Design: Using RNA sequencing (RNAseq), we analyzed transcrip-
tome changes in AT from 191 obese, nondiabetic patients within a
multicenter, controlled dietary intervention. Expression changes were
associated with outcomes after an 8-wk LCD (800–1000 kcal/d) and
6 mo after the LCD. Results were validated by using quantitative
reverse transcriptase-polymerase chain reaction in 350 subjects from
the same cohort. Statistical models were constructed to classify weight
maintainers or glycemic improvers.
Results:With RNAseq analyses, we identified 1173 genes that were
differentially expressed after the LCD, of which 350 and 33 were
associated with changes in body mass index (BMI; in kg/m2) and
Matsuda index values, respectively, whereas 29 genes were associ-
ated with both endpoints. Pathway analyses highlighted enrichment
in lipid and glucose metabolism. Classification models were con-
structed to identify weight maintainers. A model based on clin-
ical baseline variables could not achieve any classification
(validation AUC: 0.50; 95% CI: 0.36, 0.64). However, clinical
changes during the LCD yielded better performance of the
model (AUC: 0.73; 95% CI: 0.60, 0.87]). Adding baseline ex-
pression to this model improved the performance significantly
(AUC: 0.87; 95% CI: 0.77, 0.96; Delong’s P = 0.012). Similar
analyses were performed to classify subjects with good glyce-
mic improvements. Baseline- and LCD-based clinical models
yielded similar performance (best AUC: 0.73; 95% CI: 0.60,
0.86). The addition of expression changes during the LCD im-
proved the performance substantially (AUC: 0.80; 95% CI: 0.69,
0.92; P = 0.058).
Conclusions: This study investigated AT transcriptome alterations
after an LCD in a large cohort of obese, nondiabetic patients. Gene
expression combined with clinical variables enabled us to distin-
guish weight and glycemic responders from nonresponders. These
potential biomarkers may help clinicians understand intersubject
variability and better predict the success of dietary interventions.
This trial was registered at clinicaltrials.gov as NCT00390637.
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INTRODUCTION
Obesity is characterized by an excess of fat mass that af-
fects adipocyte metabolism and associates with comorbidities
such as cardiovascular disease, insulin resistance, type 2 di-
abetes (T2D), and cancer (1–3). Dietary interventions aim to
reduce fat mass, restore normal adipose tissue (AT) function,
and improve dysfunctions linked with the metabolic syndrome
(4, 5). Yet, high variability is observed in the capacity to lose
and maintain weight (6). Weight loss generally leads to an im-
provement of glycemic control (4, 5), but this corresponds to an
average improvement and may not be true for each subject. We
demonstrated that among subjects with strong weight loss (.8%
of initial body mass), only half of these subjects had sustain-
able glycemic control improvements (7). The plasticity of AT
has been studied in response to weight loss through expression
studies either for candidate genes with a large sample size or
at the transcriptome-level with a small sample size (8–14).
However, to date our understanding remains limited regarding
the link between AT gene expression changes, and weight and
glycemic outcomes of a low-calorie diet (LCD). We in-
vestigated transcriptome-wide differences between 20 weight
maintainers (0–10% weight regained) and 20 weight regainers
(.50% weight regained) and highlighted differences in fatty
acid metabolism, citric acid cycle, oxidative phosphorylation,
and apoptosis pathways (14). By design, the scope was re-
stricted to differences between extreme responders. Therefore,
our knowledge of subjects with intermediate responses remains
insufficient for stratification purposes and underscores the need
for biomarkers (7, 15). In addition, although the role of the
b cell dysfunction and peripheral insulin resistance are well
established in T2D development (16), the contribution of AT
to T2D remains unclear. Recently, a measure of AT insulin
resistance was shown to be a prognostic marker of insulin re-
sistance and T2D progression (17), indicating that the pro-
gressive decline in b cell function correlates with a progressive
increase in AT insulin resistance and dyslipidemia. This finding
further emphasizes the importance of AT plasticity in response
to LCD interventions. In this report, we studied the tran-
scriptome of overweight and obese, nondiabetic subjects, from
the DiOGenes (Diet, Obesity and Genes) study. The subjects
followed an 8-wk LCD and a 6-mo weight-maintenance diet
intervention (18). We analyzed a large RNA sequencing
(RNAseq) dataset (191 subjects 3 2 time points) from AT
biopsies and identified genes that were differentially expressed
and associated with clinical outcomes after an LCD. The ex-
pression changes of these genes were then validated by using
RT-qPCR in a larger sample size (350 subjects 3 2 time-
points). Finally, we investigated whether these gene expres-
sion changes could distinguish responders from nonresponders
6 mo after LCD.
METHODS
Ethics
The study was performed according to the latest version of the
Declaration of Helsinki. Local ethics committees approved of
all procedures that involved human participants, and written,
informed consent was obtained from all participants.
Study design
The DiOGenes study is a pan-European, multicenter, ran-
domized controlled dietary intervention program (NCT00390637).
The study was conducted in 8 European countries: Netherlands,
Denmark, United Kingdom, Greece, Bulgaria, Germany, Spain,
and Czech Republic. The study has been described in detail
previously (18, 19), and a summary of the study is shown inFigure
1A. Briefly, overweight or obese nondiabetic subjects followed an
LCD for 8 wk. The LCD provided 800 kcal/d with the use of a
meal-replacement product (Modifast, Nutrition et Sante´ France).
Participants could also eat#400 g vegetables/d (corresponding to a
maximal addition of 200 kcal/d). Subjects who lost$8% of weight
were then included in a 6-mo weight-maintenance diet phase
and followed one of 5 diets (a 232 factorial combination diet of
low and high protein and glycemic index or a control diet).
In total, 938 participants were included for the LCD in-
tervention, and 773 (82%) achieved the 8% weight loss and were
included in the weight-maintenance diet. Among those 773 par-
ticipants, 548 (71%) completed this 6-mo weight-maintenance
intervention. The dropout rates (18% for the LCD and 29%
for weight maintenance) have been discussed in detail previously
(18) and are in line with reports from other dietary studies (20–22).
FIGURE 1 Flowcharts of DiOGENES intervention and expression stud-
ies. (A) Flowchart of the DiOGENES dietary intervention. (B) Flowchart of
the DiOGENES gene expression analyses (path 1: discovery analyses with
the use of RNAseq; path 2: validation analyses with the use of RT-qPCR).
CID, clinical investigation day; DiOGENES, Diet, Obesity and Genes; LCD,
low-calorie diet; QC, quality control; RT-qPCR, reverse transcription quan-
titative polymerase chain reaction; RNAseq, RNA sequencing.
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Gene expression analyses by using RNAseq
Total RNA was extracted from abdominal subcutaneous AT
needle biopsies as previously described (23). Gene expression
was then examined by using 100-nucleotide long paired-end
RNA sequencing with an Illumina HiSeq 2000 of libraries
prepared by using the Illumina TruSeq kit following the man-
ufacturer’s standard protocols. Sequencing was performed for a
total of 550 samples corresponding to 275 subjects having both
the baseline and after-weight-loss time points (Figure 1B). De-
multiplexing was carried out with Casava (24); the resulting
FASTQ files were then mapped onto the human genome
(GRCh37 assembly) with RNA-STAR (25) with the use of default
parameters. Sequencing quality was evaluated by using FastQC
(26). Mapping quality was assessed by using Rsamtools (27).
Multimapper reads, reads with .5 mismatches, as well as PCR
duplicates, were subsequently discarded.
For each sample, the number of reads mapping onto genes was
retrieved by using GenomicAlignments (28). Annotation was
performed by using 64,102 genes from the GRCh37.75 assembly
generated with the use of the AnnotationDbi R package (29).
Only reads with both ends mapping onto one single gene were
considered.
Samples were discarded if they had unusually low sequencing
depths (,1 million reads), unusually low mapping percentages
(,60%), unusually low final mapping percentages (,40%),
highly variable sequencing depths across replicates (SD .5
million reads), and highly variable sequencing quality across
replicates (SD .5). On feature annotation, samples were dis-
carded if they had unusually low percentages of reads annotated
to genes (,75%) and samples with unusually few detected
genes (,25,000). Principal component analyses on expression
levels were also performed to exclude outlier samples and did
not reveal sex or country effects. After all QC steps, 191 subjects
remained with data for both time points. Expression data are
available from the Gene Expression Omnibus under accession
GSE95640.
Validation by using RT-qPCR assays
Complementary DNA was prepared from 500 ng total RNA
and processed by using the Biomark HD system with 96.96
Dynamic Array IFC (BioMark) and TaqMan assays (Applied
Biosystems) following the protocol described by Viguerie et al.
(23). Raw data were obtained by using the Fluidigm software
(Real-time PCR Analysis V4.1.1; BioMark) and were checked
by using the graphical representation of plate layout.
Duplicate gene raw Ct values were averaged and then normal-
ized to a reference gene as described by Viguerie et al. (23).
Relative gene expression (30) was calculated as 22DCT. Of the
29 genes identified in RNAseq analyses to be associated
with BMI (in kg/m2) and Matsuda outcomes, 4 genes [Ensembl
gene identifier (ENSG) 00000230058, ENSG00000236404,
ENSG00000264968, ENSG00000266968] did not have any
available Taqman probes and could not be tested. During
quality-control checks, 7 genes [aldo-keto reductase family
1 member C2 (AKR1C2), keratin 5 (KRT5), Rieske Fe-S domain
containing (RFESD), fibulin 7 (FBLN7), myosin heavy poly-
peptide 1 (MYH1), protein tyrosine phosphatase, receptor type
T (PTPRTI) , and spermatogenesis associated 9 (SPATA9)] were
found with very low expression amounts. Their respective Ct
values were close to detection limits, indicating the measure-
ments were not reliable. Those 7 genes were discarded from
further analyses. Principal component analysis of the expression
fold-change on the quality-controlled dataset did not identify
any outliers and did not reveal sex or country effects.
Expression amounts in AT fractions
The same 18 genes that were successfully quantified in the
RT-qPCR validation phase were also investigated in different
AT fractions [isolated adipocytes, stromal vascular fraction
(SVF), and total abdominal subcutaneous AT] from 7 women
[age: 27–50 y, BMI (mean 6 SEM): 25.3 6 4.5] undergoing
plastic surgery at the University Hospital of Toulouse. Gene
expression was measured by using the same TaqMan assays
mentioned above. The study was approved by the ethical com-
mittee of the University Hospital of Toulouse and conformed to
the Declaration of Helsinki.
Statistical analyses
Differential expression analyses
Analysis of differentially expressed genes during the LCDwas
performed by using DESeq2 (31). Analyses were adjusted for
sex, age, and center. Adjustment for multiple testing was per-
formed by using the Benjamini-Hochberg (32) false discovery
rate (FDR) method. Genes were considered significantly dif-
ferentially expressed if their FDR-adjusted P value was ,10%
and their absolute log2 fold-change was $0.2.
Functional analyses
Pathway and enrichment analyses were performed by using the
EnrichR tool (33). Statistical significance was set at an FDR-
adjusted P value ,5%. Network-based gene set enrichment
analyses were also performed by using the EnrichNet tool (34).
Association with clinical outcomes
Genes differentially expressed were tested for association with
clinical endpoints by using linear mixed effect models adjusting
for sex and age as fixed effects and center as a random effect. For
RNAseq data (discovery analyses), normalized gene counts were
obtained from the DESeq2 package (31) after running the dif-
ferential expression analysis. For qRT-PCR data (validation
analyses), the difference in relative gene expression value was
used (22DDCt). For discovery analyses, FDR thresholds were
arbitrarily set at 5% for BMI outcomes and 10% for Matsuda
outcomes. For validation analyses, statistical significance was
set at an FDR-adjusted P value ,5%.
Expression analysis of AT fractions
The difference in expression pattern between isolated adipo-
cytes and SVFs was assessed by using a Kruskal-Wallis paired
test. Adjustment for multiple testing was performed by using the
Benjamini-Hochberg (32) procedure.
Expression quantitative trait loci analyses
Genotyping was performed by using Illumina 660 single
nucleotide polymorphism (SNP) arrays, followed with imputation
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based on the 1000 Genome European reference panel (35) and by
using Minimach3 (36). The principal component analyses on
genotype data did not reveal any strong population stratification.
Linear mixed models were used to test quantitative trait loci as-
sociations between SNPs and log2-transformed values of frag-
ments per kilobase of transcript per million mapped reads.
Expression was adjusted for age, sex, BMI, and center. Analyses
were performed for baseline expression amounts (adjusted for
baseline BMI) and change in expression amounts during the LCD
(adjusted for BMI changes). The GCTA software (37) was used
for linear mixed model computation with the “loco” option. cis–
Expression quantitative trait loci (eQTL) effects were tested by
investigating SNPs within 1 Mb of each gene. Adjustment for
multiple testing was performed by using the simpleM method
(38). Significance levels were set at an adjusted a of 5%.
Predictive analyses
These analyses aim to construct models to distinguish (clas-
sify) 2 classes of patients: those with BMI improvement better
than the median population’s improvement compared with the
remaining patients having less improvement. This improvement
was defined as the percentage of changes after the weight-
maintenance diet phase (6-mo after the LCD) compared with
baseline. Similar analyses were also performed for Matsuda
index improvement, with the 2 classes defined by patients
having a Matsuda index improvement higher or lower than the
median population’s improvement.
In these analyses, several types of models were tested:
 A clinical model based on baseline BMI, Matsuda index,
sex, and age;
 A model including variables from the clinical model to-
gether with baseline gene expression;
 A model including variables from the best clinical model,
with gene expression changes during LCD;
 A model including variables from the best clinical model,
with baseline gene expression; and
 A model based on baseline clinical variables and baseline
gene expression.
The RT-qPCR dataset (n = 350 subjects) was randomly sep-
arated into a training set (for model fitting) and a validation set
(to assess the model performance). The training dataset included
75% of the whole RT-qPCR dataset. Data were standardized
(mean-centered and scaled to unit variance), and training was
performed by using 10-fold cross-validation repeated 5 times. In
the training phase, the best classification model was identified
based on AUC from the receiving operating characteristic
(ROC) curve. Models were fitted by using a generalized linear
model with the binomial family distribution. Model training and
evaluation were performed by using the caret framework (39).
Results from the model evaluation on the validation set are
presented in the form of ROC curves. Superiority of a model
compared with another was tested with a one-sided Delong
test (40), a nonparametric method used to compare ROC
AUCs. Simplification of the models was attempted by using
the recursive feature elimination. Values are expressed as
means 6 SEMs.
RESULTS
Baseline characteristics and overall clinical outcome
Baseline characteristics of the participants are described
in Table 1. Participants were on average 41 y old, had a base-
line BMI of 34.62 6 0.22, and a baseline Matsuda index of
4.61 6 0.22.
After the LCD intervention, participants lost on average
10.82% of their initial body weight (95% CI: 10.33, 11.38) and
had glycemic control improvements (mean Matsuda index
change: +2.29; 95% CI: +1.85, +2.73). A modest, yet significant,
correlation was found between weight loss and glycemic im-
provements (Pearson’s r = 20.16; 95% CI: 20.31, 20.01;
P = 0.036). In addition, moderate variability was observed in
weight loss [relative SD (RSD) = 25% for BMI changes], but
high variability was found in glycemic improvements (RSD = 120%
for Matsuda changes). Figure 2A illustrates the variability in
clinical outcomes and shows that w15% of the subjects had no
improvements in glycemic control (changes in Matsuda index, 0),
despite a weight loss .10% of initial body weight.
Differential expression analyses during the LCD and
association with clinical outcomes
We assessed gene expression changes in AT biopsies during
the LCD intervention. We identified 1173 genes differentially
expressed, of which 350 were significantly associated with
changes in BMI (Supplemental Table 1) and 33 were associated
with changes in Matsuda index (Supplemental Table 2). In-
terestingly, despite the modest correlation between BMI and
Matsuda index changes, nearly all (29 of 33) of the genes
TABLE 1
Subject characteristics1
All (n = 191) Women (n = 121) Men (n = 70) P2
Baseline
Age, y 41.63 6 0.44 41.24 6 0.56 42.31 6 0.69 0.2271
BMI, kg/m2 34.62 6 0.33 34.89 6 0.43 34.14 6 0.53 0.2687
Weight, kg 99.49 6 1.22 95.07 6 1.34 107.13 6 2.10 ,0.001
Matsuda index 4.61 6 0.22 5.01 6 0.29 3.97 6 0.33 0.0207
Weight loss on LCD, kg 210.86 6 0.26 29.91 6 0.27 212.51 6 0.50 ,0.001
Weight loss on LCD, % 210.82 6 0.19 210.36 6 0.21 211.61 6 0.36 0.0036
Change in Matsuda index on LCD 2.29 6 0.22 2.07 6 0.25 2.66 6 0.43 0.2283
1Values are means 6 SEs. LCD, low-calorie diet.
2 t Test comparison of the differences between men and women.
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associated with changes in Matsuda index were also associated
with changes in BMI. Table 2 provides a list of these 29 genes,
including their log2 fold-change in expression. Most of these
genes were downregulated during the LCD, except 5 genes that
were upregulated [FBLN7, gasdermin B (GSDMB), complement
component 7 (C7), ENSG00000264968, and PTPRT].
Pathway and enrichment analyses
A pathway analysis identified 4 KEGG pathways significantly
enriched in BMI hits (Supplemental Table 3) pertaining to fatty
acid metabolism [including peroxisome proliferator-activated
receptor (PPAR) signaling] and to AMPK signaling. Enrich-
ment in the fatty acid metabolism pathway was defined by
13 genes [acetyl-CoA carboxylase alpha (ACACA), acyl-CoA
dehydrogenase, long chain (ACADL), acyl-CoA oxidase 1
(ACOX1), acyl-CoA synthease long-chain familiy member 1
(ACSL1), diazepam binding inhibitor (DBI), ELOVL fatty acid
elongase 5 (ELOVL5), fatty acid desaturase 2 (FADS2), malic
enzyme 1 (ME1), mitochondrial trans-2-enoyl-CoA reductase
(MECR), phosphoenolpyruvate carboxykinase 2 (PCK2), pro-
tein tyrosine phosphatase-like B (PTPLB), stearoyl-CoA
desaturase (SCD), and solute carrier family 27 member 2
(SLC27A2)]. All these genes, except PCK2, were downregulated
during the LCD. The AMPK pathway was mostly defined by
ACACA, cyclin D1 (CCDN1), fructose-bisphosphatase 1
(FBP1), glycogen synthase (GYS) 1, GYS2, leptin (LEP), PCK2,
protein phosphatase 2 scaffold subunit abeta (PPP2R1B), and
SCD genes, with all genes except PCK2 and FBP1 being
downregulated. To address known limitations from pathway
analyses (34, 41, 42), we repeated these analyses using different
annotation databases (Reactome, Gene Ontology). This con-
firmed the enrichment in pathways linked with lipid and glucose
metabolism (Supplemental Table 3). Enrichment with the use of
the MGI Mammalian Phenotype ontology (43) identified sig-
nificant enrichments in lipid homeostasis (MP0002118) and
liver physiology (MP0000609) (see constituent genes in Sup-
plemental Table 3) and marginal enrichment in glucose ho-
meostasis (FDR-adjusted P = 0.096). Network-based gene set
enrichment analyses (34) also confirmed the significant enrich-
ment in fatty acid metabolism (PPAR signaling and biosynthesis
of unsaturated fatty acids) and marginal enrichment in several
pathways related to glucose homeostasis.
Results validation by using RT-qPCR
From the identified 29 genes in the RNAseq analyses, 18 were
quantified with RT-qPCR in all available DiOGenes RNA
samples (n = 350 subjects) and passed the quality-control pro-
cedure (see Methods). With these data, we confirmed that all
18 genes were significantly differentially expressed during the
LCD (Supplemental Table 4). The direction of change was also
consistent with results from RNAseq, with GSDMB and C7
being upregulated and all remaining genes being downregulated.
To complete the analysis, we reassessed the association be-
tween changes in expression and LCD clinical outcomes. Full
results are shown in Supplemental Table 4, and a simplified
overview is shown in Figure 2B. Fifteen of eighteen genes were
significantly associated with BMI changes. Two additional genes
[aldo-keto reductase family 1 member C3 (AKR1C3) and
FIGURE 2 Results summary from the RT-qPCR analyses. (A) Correlation between weight loss and glycemic improvement changes during the LCD
(Pearson’s r = 20.16; 95% CI: 20.31,20.01; P = 0.036). About 15% of the subjects had a change in the Matsuda index of ,0. The fitted line corresponds to
a robust linear regression, with the gray area representing its SE. (B) Processed summary of the association between gene expression changes during the LCD
and clinical outcomes during the LCD or during the 6-mo weight-maintenance diet phase. Association was tested by using linear mixed effect models. Color
indicates statistical significance, with FDRs below a given threshold. For example, red shows associations with FDR ,0.05. For associations having FDR
,15%, the sign of correlation between expression changes and clinical outcomes is indicated. AKR1C3, aldo-keto reductase family 1 member C3; AQP1,
aquaporin 1; CAV2, caveolin 2; C7, complement component 7; ELOVL5, ELOVL fatty acid elongase 5; FAM198B, family with sequence similarity 198
member B; FDR, false discovery rate; GSDMB, gasdermin B; HSPB7, heat shock protein family B (small) member 7; INMT, indolethylamine N-methyl-
transferase; LCD, low-calorie diet; LEP, leptin; LOX, lysyl oxidase; ME1, malic enzyme 1; MTCH2, mitochondrial carrier 2; NPY1R, neuropeptide Y
receptor Y1; PPAP2A, phosphatidic acid phosphatase type 2A; RT-qPCR, reverse transcription quantitative polymerase chain reaction; SPARC, secreted
protein acidic and cysteine rich; VGLL3, vestigial like family member 3; VLDLR, very low density lipoprotein receptor.
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vestigial like family member 3 (VGLL3)] had marginal associ-
ations with BMI changes (FDR-adjusted P , 0.15). Four genes
were significantly associated with changes in the Matsuda
index [lysyl oxidase (LOX), LEP, mitochondrial carrier 2
(MTCH2), and GSDMB)], and 4 additional genes [ELOVL5,
heat shock protein family B (small) member 7 (HSPB7), neu-
ropeptide Y receptor Y1 (NPY1R), and very low density lipo-
protein receptor (VLDLR)] showed a trend with corrected
P value ,15%.
The association between changes in expression during the LCD
and weight outcomes, 6 mo after LCD, was also tested. Nine genes
were found significantly associated with, BMI and 5 genes were
associated with the Matsuda index 6 mo after LCD (Figure 2B).
Using a less conservative threshold (FDR-adjusted P value
,0.1), we identified 2 additional genes (LEP and C7) associ-
ated with BMI and 9 additional genes associated with the
Matsuda index.
The directionality of correlation between expression changes
and clinical outcomes is indicated in Figure 2B. All downregulated
genes had a positive correlation with BMI changes, indicating that
downregulation of gene expression correlated with weight loss and
maintenance. Conversely, these genes had a negative correlation
with Matsuda outcomes, reflecting the correlation between gene
downregulation and glycemic improvements (improvement of
insulin sensitivity). The 2 upregulated genes (C7 andGSDMB) had
a negative correlation with BMI outcomes and a positive corre-
lation with Matsuda outcomes.
Predictive models
To further challenge the potential of the 18 identified genes
as biomarkers, we constructed models to predict subjects
with distinct clinical outcomes 6 mo after the LCD (see
Methods).
TABLE 2
List of genes differentially expressed during the LCD and associated with both weight and glycemic LCD outcomes1










Association with BMI changes
Association with Matsuda
index changes
P Adjusted P P Adjusted P
ENSG00000065833 ME1 64.18 20.3247 1.16 3 10259 1.36 3 10205 1.16 3 10204 2.94 3 10203 8.01 3 10202
ENSG00000113140 SPARC 1225.38 20.2722 1.61 3 10252 2.64 3 10212 1.71 3 10209 4.96 3 10204 3.13 3 10202
ENSG00000109919 MTCH2 45.56 20.229 8.14 3 10251 1.62 3 10205 1.32 3 10204 4.84 3 10203 9.47 3 10202
ENSG00000113083 LOX 35.49 20.295 3.08 3 10242 2.53 3 10207 6.01 3 10206 3.66 3 10204 3.13 3 10202
ENSG00000067113 PPAP2A 78.59 20.214 1.00 3 10245 2.11 3 10205 1.64 3 10204 4.69 3 10203 9.47 3 10202
ENSG00000012660 ELOVL5 202.07 20.2428 8.05 3 10241 2.69 3 10204 1.20 3 10203 4.56 3 10204 3.13 3 10202
ENSG00000164125 FAM198B 51.46 20.2336 2.68 3 10238 9.25 3 10205 5.23 3 10204 4.59 3 10203 9.47 3 10202
ENSG00000144152 FBLN7 0.85 0.3216 2.41 3 10237 1.82 3 10204 8.56 3 10204 4.20 3 10203 9.47 3 10202
ENSG00000105971 CAV2 129.47 20.2226 3.24 3 10238 4.70 3 10206 4.90 3 10205 1.27 3 10203 5.83 3 10202
ENSG00000174697 LEP 503.49 20.2991 1.50 3 10238 6.88 3 10209 3.41 3 10207 6.13 3 10206 3.48 3 10203
ENSG00000196139 AKR1C3 74.88 20.2473 1.91 3 10231 8.85 3 10206 8.39 3 10205 3.80 3 10203 9.37 3 10202
ENSG00000230058 ENSG00000230058 7.56 20.3348 2.11 3 10228 5.22 3 10204 1.97 3 10203 9.96 3 10204 5.55 3 10202
ENSG00000145757 SPATA9 3.76 20.3257 4.01 3 10230 2.37 3 10206 2.94 3 10205 5.54 3 10203 9.76 3 10202
ENSG00000186081 KRT5 1.65 20.4236 4.00 3 10224 4.65 3 10206 4.90 3 10205 5.68 3 10203 9.76 3 10202
ENSG00000164128 NPY1R 87.12 20.2762 8.48 3 10230 5.42 3 10207 8.96 3 10206 4.66 3 10204 3.13 3 10202
ENSG00000147852 VLDLR 38.69 20.2795 8.87 3 10227 1.46 3 10209 1.35 3 10207 5.67 3 10203 9.76 3 10202
ENSG00000151632 AKR1C2 137.58 20.2147 7.63 3 10224 2.74 3 10205 2.01 3 10204 4.58 3 10203 9.47 3 10202
ENSG00000240583 AQP1 132.57 20.2171 9.44 3 10222 1.07 3 10204 5.72 3 10204 2.02 3 10203 8.01 3 10202
ENSG00000175449 RFESD 0.76 20.2223 1.41 3 10219 6.22 3 10204 2.27 3 10203 1.34 3 10203 5.83 3 10202
ENSG00000206538 VGLL3 17.64 20.2103 3.81 3 10220 6.83 3 10204 2.42 3 10203 3.56 3 10204 3.13 3 10202
ENSG00000241644 INMT 5.37 20.2718 6.29 3 10220 6.70 3 10204 2.39 3 10203 3.97 3 10203 9.37 3 10202
ENSG00000073605 GSDMB 6.78 0.2488 3.17 3 10216 5.19 3 10205 3.22 3 10204 2.46 3 10204 3.13 3 10202
ENSG00000236404 ENSG00000236404 4.83 20.275 2.17 3 10217 3.44 3 10207 7.10 3 10206 5.61 3 10203 9.76 3 10202
ENSG00000112936 C7 18.01 0.2618 2.13 3 10213 3.90 3 10205 2.59 3 10204 2.97 3 10203 8.01 3 10202
ENSG00000173641 HSPB7 81.79 20.2279 4.52 3 10216 4.92 3 10207 8.37 3 10206 8.76 3 10205 2.48 3 10202
ENSG00000266968 ENSG00000266968 4.12 20.2858 1.97 3 10213 2.95 3 10209 2.11 3 10207 4.22 3 10204 3.13 3 10202
ENSG00000264968 ENSG00000264968 0.83 0.3305 1.38 3 10210 4.21 3 10205 2.72 3 10204 2.64 3 10203 8.01 3 10202
ENSG00000196090 PTPRT 0.29 0.2379 2.94 3 10210 1.11 3 10204 5.88 3 10204 2.23 3 10203 8.01 3 10202
ENSG00000109061 MYH1 2.60 20.2547 8.96 3 10207 2.17 3 10208 8.73 3 10207 2.72 3 10203 8.01 3 10202
1 The differential expression was tested by using the DESeq2 framework, and the association between the change in gene expression and clinical
outcomes was assessed by using linear mixed effect models. AKR1C2, aldo-keto reductase family 1 member C2; AKR1C3, aldo-keto reductase family 1
member C3; AQP1, aquaporin 1; CAV2, caveolin2; C7, complement component 7; ELOVL5, ELOVL fatty acid elongase 5; FAM198B, family with sequence
similarity 198 member B; FBLN7, fibulin 7; FDR, false discovery rate; FPKM, fragments per kilobase of transcript per million mapped reads; FC, fold-
change; GSDMB, gasdermin B; HSPB7, heat shock protein family B (small) member 7; ID, identifier; INMT, indolethylamine N-methyltransferase; KRT5,
keratin 5; LCD, low-calorie diet; LEP, leptin; LOX, lysyl oxidase; ME1, malic enzyme 1; MTCH2, mitochondrial carrier 2; MYH1, myosin heavy polypeptide
1; NPY1R, neuropeptide Y receptor Y1; PPAP2A, phosphatidic acid phosphatase type 2A; PTPRT, protein tyrosine phosphatase, receptor type T; RFESD,
Rieske Fe-S domain containing; SPARC, secreted protein acidic and cysteine rich; SPATA9, spermatogenesis associated 9; VGLL3, vestigial like family
member 3; VLDLR, very low density lipoprotein receptor.
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For BMI analyses, 2 classes were defined: 1) subjects with
BMI changes greater than the median population’s change and
2) the remaining subjects having less weight maintenance. Next,
we defined a clinical model based only on baseline clinical
variables (BMI, Matsuda index, sex, and age). This model had
very poor classification performance (ROC AUC: 0.50; 95% CI:
0.36, 0.64; Figure 3A), equivalent to a random classification.
We next assessed a clinical model using clinical changes during
the LCD (changes in weight and the Matsuda index, with base-
line age and sex). This model, referred to as the “LCD clinical
model,” had significantly better performance with (AUC: 0.73;
95% CI: 0.60, 0.87) and was kept for subsequent analyses. Using
AT transcriptomics (RT-qPCR) data, we explored whether the
classification performance could be further improved. To this
aim, 2 additional models were evaluated:
 A model combining changes in clinical variables during the
LCD, together with changes in AT gene expression during
LCD. This model was referred to as the “LCD expression +
LCD clinical model.”
 A model combining changes in clinical variables during
LCD, together with baseline gene expression. This model
was referred to as the “baseline expression + LCD clinical
model.”
The first model yielded slightly higher performance (AUC:
0.79; 95%CI: 0.67, 0.91). The second model provided even better
performance (AUC: 0.87; 95% CI: 0.77, 0.96) and significantly
outperformed the LCD clinical model (Delong P = 0.012) and
LCD expression + LCD clinical model (P = 0.029).
We also investigated a model combining baseline clinical var-
iables with baseline expression amounts (“baseline expression +
baseline clinical”), potentially the easiest to use in a clinical
setting. This model achieved better performance than the base-
line clinical model (AUC: 0.66; 95% CI: 0.52, 0.79). However,
such performance remained lower than all models based on
LCD clinical changes (Figure 3A).
FIGURE 3 Results from predictive models. Panels A and B show receiver operating characteristic curves showing classification performance as obtained
on a validation dataset for classification of weight maintainers (A) and classification of subjects with glycemic improvements after the 6-mo follow-up (B).
Two clinical models were fitted, one with the use of baseline variables (BMI, Matsuda index, sex, and age) and the second model with the use of the same
variables with BMI and Matsuda index changes during the LCD. The best clinical model was then combined with the expression data of 18 genes. Two models
were derived: one with the use of baseline expression, the second with the use of expression changes during the LCD; only the best combined model is shown
in the plot. For comparison, a combined model based only on baseline variables (clinical and expression) is also displayed. Classification models were
constructed with the use of GLMs with a binomial function. Panels C and D show the relative importance of the predictors in the best identified models with
panel C as the best model for the prediction of weight maintainers and panel D as the best model for the prediction of subjects with glycemic improvements.
Importance is defined according to the z scores from the GLM model and is relative to the top predictor (the one with the highest z score). AKR1C3, aldo-keto
reductase family 1 member C3; AQP1, aquaporin 1; CAV2, caveolin2; C7, complement component 7; ELOVL5, ELOVL fatty acid elongase 5; FAM198B,
family with sequence similarity 198 member B; GLM, generalized linear model; GSDMB, gasdermin B; HSPB7, heat shock protein family B (small) member
7; INMT, indolethylamine N-methyltransferase; LCD, low-calorie diet; LEP, leptin; LOX, lysyl oxidase; ME1, malic enzyme 1; MTCH2, mitochondrial
carrier 2; NPY1R, neuropeptide Y receptor Y1; PPAP2A, phosphatidic acid phosphatase type 2A; SPARC, secreted protein acidic and cysteine rich; VGLL3,
vestigial like family member 3; VLDLR, very low density lipoprotein receptor.
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Figure 3C shows the features ranked by relative importance
for the best identified model (“baseline expression levels with
changes in clinical variables during LCD”). Change in BMI
during the LCD was the strongest predictor of weight mainte-
nance, with baseline MTCH2, family with sequence similarity
198 member B (FAM198B), GSDMB, and phosphatidic acid
phosphatase type 2A (PPAP2A) gene expression having very
strong contributions to the model. Validation AUCs from all
possible pairwise combinations of clinical and transcriptomics
models are available in Supplemental Table 5, and their cor-
responding ROC curves are displayed in Supplemental Figure
1. Additional details about the 2 BMI groups can be found in
Supplemental Tables (see Supplemental Table 6 for clinical
characteristics, Supplemental Table 7 for a summary of gene
expression, and Supplemental Table 8 for the full details of the
best classification model, as obtained during the training phase).
For changes in Matsuda index, we performed similar analyses
and defined 2 groups of patients according to changes higher or
lower than the median population’s change. Both baseline and
LCD clinical models yielded good performance (Figure 3B).
The baseline clinical model had a AUC of 0.73 (95% CI: 0.60,
0.86), and the LCD clinical model had an AUC of 0.72 (95% CI:
0.58, 0.85). Deriving a baseline expression + baseline clinical
model provided similar performance (AUC: 0.73; 95% CI: 0.60,
0.86). Thus, between these models, the simpler model (based
only on clinical variables) would be preferred.
However, the model combining baseline clinical variables and
changes in gene expression during the LCD had the highest
performance (AUC: 0.80; 95% CI: 0.69, 0.92; Figure 3B). This
model had marginally higher performance than the baseline clin-
ical model (P = 0.058) and had significantly higher performance
than the baseline expression + baseline clinical (P = 0.035).
Repeating these analyses with the use of the LCD clinical model
reached the same conclusions. A summary from all tested models
is presented in Supplemental Table 5, and all corresponding
ROC curves are displayed in Supplemental Figure 2. Figure 3D
shows the variable importance of the best model. As expected,
clinical variables have a strong contribution (the Matsuda index
and BMI are ranked as the top 2 variables), but clearly the model
benefits from several gene expression profiles. In particular, the
GSDMB, PPAP2A, NPY1R, C7, and MTCH2 are the top 5 genes
that contribute to the model.
As with the BMI classes, complete information on the char-
acteristics of the Matsuda groups and details about the best
classification model can be found in Supplemental Tables 9–11.
Finally, we checked whether adding the weight-maintenance
diet label would improve further the performance of the models.
For classification of both BMI and Matsuda classes, adding the
weight-maintenance diet label in the models did not improve
significantly the performance compared with the existing models
(Delong’s P . 0.30). We also attempted to simplify the various
models by applying a recursive feature elimination. Yet, the
simplified models did not yield better performance than the full
models. On the validation dataset, the AUCs from the simplified
models were slightly smaller than the AUCs from the full models;
however, these differences were not significant (P . 0.05). Thus,
the combination of both strong and weak predictors (e.g., genes
marginally associated with the outcomes) was useful for the
overall classification’s performance.
Expression profiles in isolated adipocytes and SVF
The 18 genes were also quantified in different AT fractions,
including total AT, isolated adipocytes, and SVF from 7 non-
DiOGenes subjects (see Methods). These analyses aimed to
distinguish genes expressed mostly in adipocytes from genes
mostly expressed in SVF. We compared expression between
paired isolated adipocytes and SVF and found that 14 of 18 genes
had significantly higher expression in adipocytes than in SVF
(corrected P , 0.05). Three genes presented higher expression
in SVF. The LOX gene was expressed significantly lower in
adipocytes than in SVF (corrected P = 0.019), and the C7 and
aquaporin 1 (AQP1) genes had marginally lower expression in
adipocytes than in SVF (corrected P = 0.067). No significant
differences were observed for indolethylamine N-methyl-
transferase (INMT) (corrected P = 0.23).
eQTL analyses
We tested whether expression of the 18 genes was under some
genetic control (eQTL effect). Using 57,854 SNPs located within
1 Mb of each gene, we assessed whether there was any cis-eQTL
effect on baseline expression or on expression fold-change
during the LCD. For baseline gene expression, only 2 SNPs
(rs73206101 and rs73208115) were significantly associated with
caveolin 2 (CAV2) gene expression (adjusted P , 0.05). These 2
SNPs were in moderate linkage disequilibrium (r2 = 0.68) with
each other. No significant cis-eQTL effect was detected for
expression changes during the LCD. By repeating this analysis
with expression fold-changes adjusted for weight loss, the
same negative results were produced. Using different type of
multiple-testing corrections (FDR, familywise error rate) also
led to the same conclusions.
DISCUSSION
In this study, we documented transcriptome-wide AT changes
in response to an LCD and the link with clinical outcomes after
the LCD. We identified 1173 genes differentially expressed
during the LCD, with most genes being downregulated. This is
consistent with previous studies (23) and in agreement with fat-
mass reduction and adaptation of the AT metabolism (44).
Pathway analyses of the 350 genes associated with BMI changes
pointed toward enrichment in lipid and glucose metabolism
pathways. This is in line with recent analyses of the DiOGenes
lipidomic data (7) showing the importance of dyslipidemia
during LCD. This is also in agreement with gene expression
findings distinguishing weight maintainers from weight regainers
(14). Enrichment analyses with the use of the 33 genes associated
with Matsuda outcomes were not performed, because this type of
analysis usually requires a larger gene set. However, the in-
dividual gene functions pointed to similar biological processes.
Nearly all genes (29 of 33) associated with glycemic im-
provements were also associated with weight loss, marking them
as potentially clinically relevant biomarkers. We thus focused on
the 29 genes associated with both endpoints, with the aim to
better understand the link between expression changes and
glycemic improvements. Remarkably, within this list, 7 of the 10
most differentially expressed genes [ME1, secreted protein acidic
and cysteine rich (SPARC), MTCH2, LOX, ELOVL5, CAV2, and
LEP] are well established in the context of obesity, T2D onset,
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or adipocyte regulation. ME1 is a known causal obesity gene
(45), SPARC is involved with adipocyte differentiation and
strongly associated with both obesity and diabetes (46), MTCH2
is a known obesity risk factor gene (47), LOX levels were found
altered on bariatric surgery (48), ELOVL5 plays a key role in
regulating triglycerides and MUFA/PUFA synthesis (49), ge-
netic polymorphisms in CAV2, in interaction with fat intake,
are associated with T2D (50), and LEP is a major hallmark
gene in weight loss and obesity (51–53). Such enrichment in
obesity biomarkers lends further credibility to our results.
RT-qPCR analyses in a larger sample set (n = 350 subjects
instead of n = 191) showed that all tested genes (18) displayed
differential expression, with a consistent direction of expression
changes compared with RNAseq results. Overall, we observed a
very strong replication of BMI hits and less replication for
Matsuda hits. The latter can be explained by numerous factors,
such as a slightly higher rate of false positives in the discovery
phase, the higher variability of Matsuda outcomes (RSD = 120%
compared with 25% for BMI outcomes), increased heteroge-
neity in the replication cohort, or simply technological differ-
ences between RNAseq and RT-qPCR leading to differences in
the dynamic range. In subsequent analyses, we kept all genes
because their known function clearly marked them as plausible
biological candidates. To assess their potential as biomarkers,
we defined 2 classes of patients: good and lesser improvers both
for BMI and Matsuda outcomes and attempted to construct
classification models. Classification of good weight maintainers
could not be achieved with a model based only on baseline
clinical variables: the performance was comparable to a random
classification. This illustrates the difficulty in predicting weight
maintenance based on initial body weight. A model based on
clinical changes during the LCD provided much better perfor-
mance. Performance was further increased, up to an AUC of
0.87, by integrating baseline gene expression. In this model,
BMI had some predictive value, and the model benefited
from several key gene expression amounts such as MTCH2,
FAM198B, GSDMB, and PPAP2A. Our choice to focus on genes
associated with both BMI and the Matsuda index potentially
excluded other relevant BMI biomarkers. Yet, with the best
model already having an AUC close to 0.87, the room for
significant improvement is limited. For classification of the
Matsuda groups, the clinical models already yielded good
performance (AUC: 0.73). Here, a model integrating baseline
gene expression did not improve the classification. By contrast,
the model using changes in expression during the LCD im-
proved the AUC by +7%, corresponding to an increase in both
sensitivity and specificity. In this model, the clinical variables,
the Matsuda index, BMI, and sex, were among the strongest
predictors (ranked as 1, 2, and 4, respectively) as expected, and
the model strongly benefited from inclusion of the following
genes: GSDMB, PPAP2A, NPY1R, C7, and MTCH2 (ranked as
3, then 5–8, respectively).
Expression analyses of 18 genes in AT fractions showed that 14
were predominantly expressed in adipocytes compared with the
SVF, whereas 3 were more specific to the SVF. Among the 18 genes,
5 encoded for secreted proteins (LEP, LOX, SPARC, C7, and
VLDLR) and may thus have potential as circulating biomarkers.
eQTL analyses revealed cis-effects on CAV2 baseline expres-
sion, and no significant eQTL effect was detected for expression
changes during the LCD in any of the 18 genes. This is
consistent with previous observations (23), where only a mar-
ginal cis-eQTL effect was found on baseline expression, and no
significant effect was detected for expression fold-changes on
LCD.
Our results are strengthened by the fact that the DiOGenes
study is the largest study of its kind, combining data both from
an LCD and a weight-maintenance diet intervention. Our ini-
tial analyses were based on a discovery RNAseq analysis, and
findings were replicated in a larger sample from the same cohort
by using RT-qPCR. Such a large sample size enabled us to per-
form classification analyses, splitting the data into training and
testing sets, and using internal cross-validation during the train-
ing phase. We could thereby maximize the use of each obser-
vation and prevent model overfitting. Further follow-up in
isolated adipocytes demonstrated the cell specificity of our find-
ings, and potential confounding factors linked with genotypes
could be excluded by eQTL analyses. Additional preclinical and
clinical studies are beyond the scope of the current study but
remain needed to fully validate the identified biomarkers and
understand the underlying molecular differences between re-
sponders and nonresponders.
In conclusion, our study demonstrates the importance of mo-
lecular phenotyping to identify potential biomarkers and studying
the possible mechanisms involved in the dynamics of weight loss
and maintenance. To our knowledge, this study is the first to link
LCD-induced transcriptome-wide alterations with weight and
glycemic outcomes in a large population of overweight and obese
patients. We propose plausible biomarkers that outperform clinical
models for classification of weight maintainers and that help in
improving clinical models for prediction of glycemic improvers.
Our methodologies and findings might benefit clinicians and
scientists by providing a better understanding of the large inter-
subject variability in response to dietary interventions.
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